Oxycodone/niacin - Acura

Drug Profile

Oxycodone/niacin - Acura

Alternative Names: Acurox with Niacin; OxyADF; Oxycodone HCl/niacin; Oxycodone/niacin; Oxycodone/niacin IR - Acura

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Acura Pharmaceuticals
  • Class Morphine derivatives; Nicotinic-acids; Opioid analgesics; Peripheral vasodilators; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 01 Dec 2011 Discontinued - Preregistration for Pain in USA (PO)
  • 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
  • 03 May 2010 Clinical trials in Pain in USA (niacin-free formulation) (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top